A detailed history of Trexquant Investment LP transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 74,424 shares of ARCT stock, worth $1.36 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
74,424
Previous 53,409 39.35%
Holding current value
$1.36 Million
Previous $1.3 Million 32.85%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$18.08 - $25.38 $379,951 - $533,360
21,015 Added 39.35%
74,424 $1.73 Million
Q2 2024

Aug 13, 2024

BUY
$24.35 - $44.39 $1.3 Million - $2.37 Million
53,409 New
53,409 $1.3 Million
Q4 2023

Feb 09, 2024

SELL
$17.71 - $32.97 $724,604 - $1.35 Million
-40,915 Reduced 78.88%
10,956 $345,000
Q3 2023

Nov 13, 2023

BUY
$25.44 - $37.35 $438,331 - $643,540
17,230 Added 49.74%
51,871 $1.33 Million
Q2 2023

Aug 11, 2023

BUY
$23.94 - $32.36 $829,305 - $1.12 Million
34,641 New
34,641 $993,000
Q4 2022

Feb 13, 2023

BUY
$14.14 - $23.06 $300,955 - $490,809
21,284 New
21,284 $360,000
Q1 2022

May 13, 2022

SELL
$17.64 - $39.57 $104,763 - $235,006
-5,939 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$34.2 - $47.56 $203,113 - $282,458
5,939 New
5,939 $220,000
Q2 2021

Aug 12, 2021

SELL
$25.79 - $42.11 $139,988 - $228,573
-5,428 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$38.75 - $86.92 $210,335 - $471,801
5,428 New
5,428 $224,000
Q2 2020

Aug 07, 2020

SELL
$12.66 - $58.27 $159,921 - $736,066
-12,632 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$9.31 - $18.26 $117,603 - $230,660
12,632 New
12,632 $172,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $487M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.